Raymond S. Norton

Raymond S. Norton

Professor of Medicinal Chemistry, Monash University
在 monash.edu 的电子邮件经过验证
被引用次数：23876
peptides structural biology malaria autoimmune disease fragment-based drug design
Anna Vulpetti

Anna Vulpetti

CADD, Novartis
在 novartis.com 的电子邮件经过验证
被引用次数：6506
Molecular Modelling Drug Design Fragment based drug design Fluorine MedChem
Martin Scanlon

Martin Scanlon

Professor of Medicinal Chemistry, Monash University
在 monash.edu 的电子邮件经过验证
被引用次数：6393
Structural Biology Fragment-based drug design
William Pomerantz

William Pomerantz

University of Minnesota
在 umn.edu 的电子邮件经过验证
被引用次数：3545
epigenetics fragment based drug design chemical biology biomolecular fluorine NMR
Christopher John Brown

Christopher John Brown

Principle Investigator
在 p53lab.a-star.edu.sg 的电子邮件经过验证
被引用次数：3538
Therapeutic peptides biophysics Fragment based drug design Ligand-Protein interactions Crystallography
Jamie Simpson

Jamie Simpson

Seaport Therapeutics
在 monash.edu 的电子邮件经过验证
被引用次数：2317
Lipids Medicinal Chemistry Fragment-based drug design Biological Chemistry Organic Chemistry
Chris Radoux

Chris Radoux

Associate Director Structural Bioinformatics, Exscientia
在 exscientia.co.uk 的电子邮件经过验证
被引用次数：2234
Molecular Modelling Structure-Based Drug Design Computer-Aided Drug Design Fragment-Based Drug Design Exscientia
Maria Håkansson, phD, Principal scientist

Maria Håkansson, phD, Principal scientist

SARomics Biostructures AB
在 saromics.com 的电子邮件经过验证
被引用次数：1863
X-ray crystallography Fragment based drug design protein charcterisation
Wenjuan Jiang

Wenjuan Jiang

Western University of Health Sciences
在 westernu.edu 的电子邮件经过验证
被引用次数：859
FEP Virtual Screening Ion Channel Nanocarriers Fragment-based Drug Design
Kenichi Mori

Kenichi Mori

Senior Director, Digital, Analytics & Technology, Astellas Pharma Inc.
在 astellas.com 的电子邮件经过验证
被引用次数：859
structure based drug design fragment based drug design chemoinformatics machine learning
1 - 10